NYSEAMERICAN : IBO
Impact BioMedical Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 3.87 USD (Oct 30, 2026, 9:38 AM EDT) · Market cap 33.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Impact BioMedical Inc. (IBO) reported revenue of 35.00K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 35.00K | 32.00K | 50.00K | |||
| Cost of Revenue | 424.00K | 424.00K | ||||
| Gross Profit | -389.00K | -392.00K | 50.00K | |||
| Selling, General & Admin | 2.96M | 1.98M | 1.83M | 1.10M | 1.11M | 992.00K |
| Research & Development | 285.00K | 340.00K | 278.00K | 1.69M | 1.23M | 1.08M |
| Other Operating Expenses | 315.00K | 417.00K | 171.00K | 119.00K | ||
| Operating Expenses | 4.71M | 3.88M | 3.40M | 4.03M | 3.45M | 3.19M |
| Operating Income | -5.09M | -4.27M | -3.40M | -4.03M | -3.40M | -3.19M |
| Interest Expense | -262.00K | -793.00K | -1.06M | -444.00K | -462.00K | -300.00K |
| Interest & Investment Income | 13.00K | 13.00K | 13.00K | 13.00K | 24.00K | 165.00K |
| Other Non Operating Income (Expenses) | 3.55M | -9.39M | 5.07M | 52.00K | 66.00K | 77.00K |
| EBT Excluding Unusual Items | -1.79M | -14.44M | 619.00K | -4.41M | -3.78M | -3.24M |
| Impairment of Goodwill | -25.09M | |||||
| Gain (Loss) on Sale of Investments | -4.10M | |||||
| Gain (Loss) on Sale of Assets | -12.00K | -12.00K | ||||
| Asset Writedown | -263.00K | |||||
| Pretax Income | -1.80M | -14.45M | -24.74M | -4.41M | -7.88M | -3.24M |
| Income Tax Expense | -2.58M | -2.58M | 33.00K | -621.00K | -1.40M | |
| Earnings From Continuing Operations | 778.00K | -11.87M | -24.77M | -4.41M | -7.25M | -1.85M |
| Minority Interest in Earnings | 13.00K | 32.00K | 62.00K | 71.00K | 204.00K | 545.00K |
| Net Income | 791.00K | -11.84M | -24.71M | -4.34M | -7.05M | -1.30M |
| Net Income to Common | 791.00K | -11.84M | -24.71M | -4.34M | -7.05M | -1.30M |
| Shares Outstanding (Basic) | 6.29M | 2.50M | 852.40K | 4.77M | 5.59M | 5.59M |
| Shares Outstanding (Diluted) | 6.29M | 2.50M | 852.40K | 4.77M | 5.59M | 5.59M |
| EPS (Basic) | 0.13 | -4.74 | -28.99 | -0.91 | -1.26 | -0.23 |
| EPS (Diluted) | 0.07 | -4.80 | -29.03 | -0.91 | -1.26 | -0.23 |
| Free Cash Flow | -508.00K | -1.89M | -2.85M | -2.87M | -2.52M | -2.03M |
| Free Cash Flow Per Share | -0.08 | -0.76 | -3.35 | -0.60 | -0.45 | -0.36 |
| Gross Margin | 100.00% | |||||
| Operating Margin | -14,557.14% | -13,343.75% | -6,808.00% | |||
| Profit Margin | 2,260.00% | -36,993.75% | -14,102.00% | |||
| Free Cash Flow Margin | -1,451.43% | -5,906.25% | -5,036.00% | |||
| EBITDA | -3.95M | -3.12M | -3.39M | -4.02M | -2.29M | -2.07M |
| D&A For EBITDA | 1.14M | 1.15M | 7.00K | 6.00K | 1.11M | 1.11M |
| EBIT | -5.09M | -4.27M | -3.40M | -4.03M | -3.40M | -3.19M |
| Revenue as Reported | 35.00K | 32.00K |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 10.00K | 3.00K | 2.00M | 1.00K | 2.00K | 46.00K |
| Cash & Short-Term Investments | 10.00K | 3.00K | 2.00M | 1.00K | 2.00K | 46.00K |
| Accounts Receivable | 5.00K | |||||
| Other Receivables | 128.00K | |||||
| Receivables | 197.00K | 203.00K | 184.00K | 331.00K | 16.00K | 197.00K |
| Inventory | 62.00K | 63.00K | ||||
| Prepaid Expenses | 51.00K | 140.00K | 263.00K | 61.00K | 1.00K | |
| Other Current Assets | 2.00K | 2.00K | 43.00K | 43.00K | ||
| Total Current Assets | 320.00K | 411.00K | 2.45M | 332.00K | 122.00K | 287.00K |
| Property, Plant & Equipment | 17.00K | 287.00K | 276.00K | |||
| Long-Term Investments | 782.00K | 4.82M | ||||
| Goodwill | 25.09M | 25.09M | 25.09M | |||
| Other Intangible Assets | 16.43M | 16.99M | 17.81M | 18.92M | 20.03M | 21.15M |
| Total Assets | 16.75M | 17.41M | 20.29M | 44.63M | 46.50M | 56.42M |
| Accounts Payable | 467.00K | 347.00K | 314.00K | 832.00K | 539.00K | 115.00K |
| Accrued Expenses | 248.00K | 194.00K | 194.00K | 230.00K | 63.00K | 6.00K |
| Short-Term Debt | 8.88M | 12.07M | 9.99M | 12.52M | ||
| Other Current Liabilities | 1.33M | 621.00K | 399.00K | |||
| Total Current Liabilities | 2.04M | 1.16M | 9.79M | 13.14M | 10.59M | 12.64M |
| Long-Term Deferred Tax Liabilities | 688.00K | 688.00K | 3.27M | 3.23M | 3.23M | 3.86M |
| Total Liabilities | 2.73M | 1.85M | 13.05M | 16.37M | 13.83M | 16.50M |
| Common Stock | 108.00K | 105.00K | 11.00K | 10.00K | 70.00K | 125.00K |
| Additional Paid-In Capital | 63.15M | 62.01M | 41.86M | 38.11M | 38.11M | 38.06M |
| Retained Earnings | -52.49M | -49.51M | -37.67M | -12.96M | -8.62M | -1.57M |
| Total Common Equity | 10.77M | 12.61M | 4.20M | 25.16M | 29.56M | 36.61M |
| Minority Interest | 3.25M | 2.95M | 2.98M | 3.04M | 3.11M | 3.31M |
| Shareholders' Equity | 14.01M | 15.55M | 7.24M | 28.26M | 32.67M | 39.92M |
| Total Liabilities & Equity | 16.75M | 17.41M | 20.29M | 44.63M | 46.50M | 56.42M |
| Total Debt | 8.88M | 12.07M | 9.99M | 12.52M | ||
| Net Cash (Debt) | 10.00K | 3.00K | -6.88M | -12.07M | -9.99M | -12.48M |
| Net Cash Per Share | 0.00 | 0.00 | -8.07 | -2.53 | -1.79 | -2.23 |
| Filing Date Shares Outstanding | 8.54M | 8.54M | 957.65K | 792.40K | 5.59M | 5.59M |
| Total Common Shares Outstanding | 8.54M | 8.29M | 911.57K | 792.40K | 5.59M | 5.59M |
| Working Capital | -1.73M | -751.00K | -7.34M | -12.80M | -10.47M | -12.36M |
| Book Value Per Share | 1.26 | 1.52 | 4.61 | 31.75 | 5.29 | 6.55 |
| Tangible Book Value | -5.66M | -4.38M | -13.61M | -18.85M | -15.57M | -9.63M |
| Tangible Book Value Per Share | -0.66 | -0.53 | -14.93 | -23.79 | -2.79 | -1.72 |
| Machinery | 30.00K | 25.00K | ||||
| Construction In Progress | 251.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | 791.00K | -11.84M | -24.71M | -4.34M | -7.05M | -1.30M |
| Depreciation & Amortization | 1.14M | 1.15M | 7.00K | 6.00K | ||
| Other Amortization | 1.11M | 1.11M | 1.11M | 1.11M | ||
| Loss (Gain) From Sale of Assets | 12.00K | 12.00K | ||||
| Asset Writedown & Restructuring Costs | 25.36M | |||||
| Loss (Gain) From Sale of Investments | 4.10M | |||||
| Stock-Based Compensation | 1.45M | 203.00K | 19.00K | |||
| Other Operating Activities | -5.47M | 7.99M | -4.03M | -71.00K | -825.00K | -1.94M |
| Change in Accounts Receivable | -1.00K | 128.00K | -128.00K | |||
| Change in Inventory | 5.00K | 7.00K | ||||
| Change in Accounts Payable | 749.00K | 470.00K | -436.00K | 293.00K | 424.00K | 106.00K |
| Change in Other Net Operating Assets | 809.00K | 124.00K | -300.00K | 271.00K | -3.00K | -3.00K |
| Operating Cash Flow | -508.00K | -1.89M | -2.85M | -2.85M | -2.24M | -2.03M |
| Capital Expenditures | -18.00K | -276.00K | ||||
| Investment in Securities | -65.00K | -4.18M | ||||
| Other Investing Activities | 3.00K | 3.00K | 2.00K | 3.00K | -8.00K | -5.28M |
| Investing Cash Flow | 3.00K | 3.00K | 2.00K | -15.00K | -349.00K | -9.46M |
| Short-Term Debt Issued | 184.00K | 1.12M | 2.55M | 11.46M | ||
| Long-Term Debt Issued | 2.87M | |||||
| Total Debt Issued | 184.00K | 184.00K | 1.12M | 2.87M | 2.55M | 11.46M |
| Short-Term Debt Repaid | -293.00K | |||||
| Total Debt Repaid | -293.00K | -293.00K | ||||
| Net Debt Issued (Repaid) | -109.00K | -109.00K | 1.12M | 2.87M | 2.55M | 11.46M |
| Issuance of Common Stock | 3.73M | |||||
| Financing Cash Flow | -109.00K | -109.00K | 4.85M | 2.87M | 2.55M | 11.46M |
| Miscellaneous Cash Flow Adjustments | -1.00K | |||||
| Net Cash Flow | -614.00K | -2.00M | 2.00M | -1.00K | -44.00K | -27.00K |
| Free Cash Flow | -508.00K | -1.89M | -2.85M | -2.87M | -2.52M | -2.03M |
| Free Cash Flow Margin | -1,451.43% | -5,906.25% | -5,036.00% | |||
| Free Cash Flow Per Share | -0.08 | -0.76 | -3.35 | -0.60 | -0.45 | -0.36 |
| Levered Free Cash Flow | 1.02M | -1.52M | -1.92M | -1.44M | -977.25K | -1.16M |
| Unlevered Free Cash Flow | 1.18M | -1.02M | -1.26M | -1.17M | -688.50K | -972.16K |
| Change in Working Capital | 1.56M | 600.00K | -608.00K | 436.00K | 421.00K | 103.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 32.47M | 52.83M | 16.68M | |||
| Enterprise Value | 32.46M | 78.72M | 25.08M | |||
| Last Close Price | 3.80 | 6.37 | 18.30 | |||
| PS Ratio | 927.61 | 1,651.05 | ||||
| PB Ratio | 3.02 | 3.40 | 2.31 | |||
| EV/Sales Ratio | 927.32 | 2,459.96 | ||||
| Debt / Equity Ratio | 1.23 | 0.43 | 0.31 | 0.31 | ||
| Net Debt / Equity Ratio | -0.00 | 0.00 | 0.95 | 0.43 | 0.31 | 0.31 |
| Net Debt / EBITDA Ratio | 0.00 | 0.00 | -2.03 | -3.00 | -4.36 | -6.02 |
| Net Debt / FCF Ratio | 0.02 | 0.00 | -2.41 | -4.21 | -3.97 | -6.16 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | |||
| Quick Ratio | 0.01 | 0.01 | 0.20 | 0.01 | 0.00 | 0.00 |
| Current Ratio | 0.16 | 0.35 | 0.25 | 0.03 | 0.01 | 0.02 |
| Return on Equity (ROE) | 23.46% | -104.16% | -139.55% | -14.46% | -19.99% | -4.52% |
| Return on Assets (ROA) | -17.79% | -14.16% | -6.54% | -5.53% | -4.13% | -3.81% |
| Return on Capital Employed (ROCE) | -34.70% | -26.30% | -32.30% | -12.80% | -9.50% | -7.30% |
| Earnings Yield | 1.74% | -22.41% | -148.12% | |||
| FCF Yield | -1.56% | -3.58% | -17.11% | |||
| Buyback Yield / Dilution | -571.61% | -193.30% | 82.14% | 14.54% | 0.00% |